Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push

View original at finance.yahoo.com
AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company is committed to invest US$15 billion in China's biotech sector through 2030

    60% confidence

  • AstraZeneca is the first multinational with end-to-end cell therapy manufacturing capability in China

    60% confidence

Data points we hold from this source

AstraZeneca AB · return 1year21.8 percent
AstraZeneca AB · return 1month-9.0 percent
AstraZeneca AB · return 1week-3.4 percent
AstraZeneca AB · return 3year33.2 percent
AstraZeneca AB · return 5year112.4 percent
AstraZeneca AB · return ytd2.2 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
AstraZeneca Deepens China Roots With Shanghai Cell Therapy Manufacturing Push — Source | Via News | Finance Via News